“We are pleased that our lead product, ResAppDx-EU is now...

“We are pleased that our lead product, ResAppDx-EU is now approved for use on both adults and children in Australia and Europe,” said Tony Keating, CEO and Managing Director of ResApp. “ResAppDx-EU offers strong health and economic benefits to telehealth providers, emergency departments and urgent care clinics in Australia and Europe, and we are excited by the scale of the opportunity and our unique position in the market. We are now growing our commercial team to support our sales, marketing and business development activities in these regions, and we are pleased to have a growing number of opportunities at various stages in our commercial pipeline.”